These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 28882182)

  • 41. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
    Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
    J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade- and mitochondria-dependent pathways.
    Wu SH; Hang LW; Yang JS; Chen HY; Lin HY; Chiang JH; Lu CC; Yang JL; Lai TY; Ko YC; Chung JG
    Anticancer Res; 2010 Jun; 30(6):2125-33. PubMed ID: 20651361
    [TBL] [Abstract][Full Text] [Related]  

  • 43. miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1.
    Gao HX; Yan L; Li C; Zhao LM; Liu W
    Mol Med Rep; 2016 Nov; 14(5):4135-4143. PubMed ID: 27666124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
    Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
    Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pterostilbene exerts anticancer activity on non-small-cell lung cancer via activating endoplasmic reticulum stress.
    Ma Z; Yang Y; Di S; Feng X; Liu D; Jiang S; Hu W; Qin Z; Li Y; Lv J; Fan C; Yan X; Li X
    Sci Rep; 2017 Aug; 7(1):8091. PubMed ID: 28808300
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer.
    Wang Y; Zhang J; Gao G; Li X; Zhao C; He Y; Su C; Zhang S; Chen X; Zhang J; Li W; Li B; Zhao J; Hou L; Wu C; Ren S; Zhou C; Zhang J
    J Thorac Oncol; 2015 Nov; 10(11):1546-52. PubMed ID: 26352533
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status.
    Li DL; Chen XR; Ma SX; Chen LK
    Thorac Cancer; 2016 Sep; 7(5):619-622. PubMed ID: 27766783
    [TBL] [Abstract][Full Text] [Related]  

  • 48. β-Apopicropodophyllin functions as a radiosensitizer targeting ER stress in non-small cell lung cancer.
    Kim JY; Cho JH; Kim EM; Shin HJ; Hwang SG; Song JY; Um HD; Park JK
    Biomed Pharmacother; 2019 May; 113():108769. PubMed ID: 30870718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
    J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.
    Das I; Gad H; Bräutigam L; Pudelko L; Tuominen R; Höiom V; Almlöf I; Rajagopal V; Hansson J; Helleday T; Egyházi Brage S; Warpman Berglund U
    Cell Death Differ; 2020 Jul; 27(7):2081-2098. PubMed ID: 31919461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases.
    Zanwar S; Noronha V; Joshi A; Patil VM; Kaushal R; Chougule A; Janu A; Mahajan A; Kapoor A; Prabhash K
    Indian J Cancer; 2017; 54(4):678-680. PubMed ID: 30082557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.
    Amin AD; Rajan SS; Liang WS; Pongtornpipat P; Groysman MJ; Tapia EO; Peters TL; Cuyugan L; Adkins J; Rimsza LM; Lussier YA; Puvvada SD; Schatz JH
    Cancer Res; 2015 Jul; 75(14):2916-27. PubMed ID: 26018086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IRE1α-TRAF2-ASK1 pathway is involved in CSTMP-induced apoptosis and ER stress in human non-small cell lung cancer A549 cells.
    Zhang J; Liang Y; Lin Y; Liu Y; YouYou ; Yin W
    Biomed Pharmacother; 2016 Aug; 82():281-9. PubMed ID: 27470364
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of a curcumin analog as an anti-cancer agent inducing ER stress-mediated apoptosis in non-small cell lung cancer cells.
    Liu Z; Sun Y; Ren L; Huang Y; Cai Y; Weng Q; Shen X; Li X; Liang G; Wang Y
    BMC Cancer; 2013 Oct; 13():494. PubMed ID: 24156374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
    Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
    Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.
    Ricciuti B; De Giglio A; Mecca C; Arcuri C; Marini S; Metro G; Baglivo S; Sidoni A; Bellezza G; Crinò L; Chiari R
    Med Oncol; 2018 Apr; 35(5):72. PubMed ID: 29666949
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI; Gautschi O
    Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non-small cell lung cancer cells via Nrf2 inhibition.
    Chen X; Wu Q; Chen Y; Zhang J; Li H; Yang Z; Yang Y; Deng Y; Zhang L; Liu B
    Br J Pharmacol; 2019 Jun; 176(12):2079-2094. PubMed ID: 30825187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PERK/eIF-2α/CHOP Pathway Dependent ROS Generation Mediates Butein-induced Non-small-cell Lung Cancer Apoptosis and G2/M Phase Arrest.
    Di S; Fan C; Ma Z; Li M; Guo K; Han D; Li X; Mu D; Yan X
    Int J Biol Sci; 2019; 15(8):1637-1653. PubMed ID: 31360107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.